TOKYO, July 30 /PRNewswire/ -- With a business plan to launch 8-10 new products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of the Zydus group, one of India’s leading integrated pharma companies & a global healthcare provider, is looking to give a big boost to its operations in the Japanese generic market which is still evolving. While the total pharma market in Japan is estimated at $ 60 bn the generic market is only about 6% of this in value terms and just 18% in volume, which is very low compared to highly genericised markets like USA and Europe. The awareness of generics in Japan is comparatively low and generics are still largely perceived as cheaper, low quality alternatives to patented drugs. The nationwide promotion and awareness campaign regarding the safety and efficacy of generics however is expected to change this perception and usage in future.
